Author | Paul G. Richardson, MD

Articles

COUNTERPOINT: Routine Use of Autologous Stem Cell Transplantation in Multiple Myeloma

August 15, 2016

Myeloma is clearly not one disease but several. In terms of treatment choices, it is increasingly evident that one size of treatment does not fit all. Moreover, as therapy is tailored to each individual patient, with the ability to mobilize and collect stem cells and retain them after successful induction/remission therapy, younger patients have choices.

Multiple Myeloma and Other Plasma Cell Dyscrasias

June 01, 2016

This management guide covers the symptoms, diagnosis, screening, staging, and treatment of multiple myeloma, smoldering myeloma, and other plasma cell dyscrasias.

IgD and IgE Variants of Myeloma: Valuable Insights and Therapeutic Opportunities

August 15, 2013

The real promise of improving patient outcomes in IgD and IgE multiple myeloma lies in multi-drug combinations, next-generation agents, and immunotherapy.

MGUS and Smoldering Myeloma: the Most Prevalent of Plasma Cell Dyscrasias

June 14, 2011

Monoclonal gammopathy of undetermined significance (MGUS) is the most prevalent of the plasma cell dyscrasias and is characterized by a low level of production of serum monoclonal (M) protein (classically less than 3 g/dL).